Navigation Links
Derma Sciences Enrolls First Patient in DSC127 Phase II Study
Date:11/3/2008

statements which may be made in this release or which are otherwise made by or on behalf of the Company. Factors which may affect the Company's results include, but are not limited to, product demand, market acceptance, impact of competitive products and prices, product development, completion of an acquisition, commercialization or technological difficulties, the success or failure of negotiations and trade, legal, social and economic risks. Additional factors that could cause or contribute to differences between the Company's actual results and forward-looking statements Include but are not limited to, those discussed in the Company's filings with the Securities and Exchange Commission.

Contact: Derma Sciences, Inc. Allen & Caron Inc

Edward J. Quilty Rudy Barrio (US Investors)

Chairman and CEO r.barrio@allencaron.com

equilty@dermasciences.com

(609) 514-4744 Brian Kennedy (media)

brian@allencaron.com

(212) 691-8087


'/>"/>
SOURCE Derma Sciences, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5

Related medicine news :

1. QUANTEL Intends to Strengthen its Dermatology/ Aesthetics Division With the Acquisition of WaveLight Aesthetic GmbH
2. Dermatologists identify North Texas leishmaniasis outbreak
3. Tissue-Growth Gene Tied to Scleroderma
4. American Academy of Dermatology Association Commends President Bush for Signing Tanning Accountability and Notification (TAN) Act
5. UltraShape(TM) Non-Invasive Fat Reduction and Body Contouring Clinical Study Results Presented at American Society for Dermatologic Surgery Annual Meeting
6. VivaScope(R) Confocal Imager May Eliminate Need for Routine Skin Biopsies for Dermatology Patients
7. Galderma Associates Itself to Cartiers Womens Initiative Awards to Recognize Female Entrepreneurs From Around the Globe
8. American Academy of Dermatology: New Study Finds Women More Likely Than Men to be Affected by Acne as Adults
9. New Study Provides Scientific Evidence That DermaLastyl Face Cream Reduces Wrinkles
10. Dermatologists Warn Fitness Enthusiasts: Dont Let Exercise-Related Skin Problems Outweigh the Benefits of Physical Activity
11. Active compounds found in Ganoderma lucidum fungus with potential to treat prostate cancer

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/27/2009)... low-emission vehicles may reduce future disease b...27 (HealthDay News) -- Encouraging city dwellers t...er much greater public health benefits than increa...s have found. , The study compared the projecte... transport scenarios for London, England, and Delh...
(Date:11/27/2009)... Specialist manufacturers who use medical load ce...ions of dollars by bringing in technology partner ...mbers of pro-active medical manufacturers are call...age of their projects, ensuring that progress will...r potentially outdated technology. , ...
(Date:11/26/2009)...g drug tetrathiomolybdate (TM) has been shown in s...disease, a disease caused by an overload of copper...wn. Very little, however, is known about how the d...led by Northwestern University researchers now has...l structure of TM bound to copper-loaded metalloch...
(Date:11/26/2009)... Research Triangle Dental (RTDental), a leading d...day announced the expansion of its services to inc.... Doug Macmillan. , Du...eased to announce that Dr. Doug Macmillan, an expe... additional advanced training seminar. RTDental&r...
(Date:11/25/2009)....,Nov.25/PRNewswire-FirstCall/-- OnyxPharmaceutic...ywillhosttwoinvestoreventsinDecember: ,, ASHB....m.ET ,, Principalinvestigatorswilldiscussdat...orrefractorymultiplemyeloma,asfeaturedatthe51stAme...itioninNewOrleans,LA.Theteleconferencewillbeginat9...
Breaking Medicine News(10 mins):Health News:More Foot Power, Less Car Pollution Best for Health 2Health News:Pro-active Manufacturers Save Millions with Advanced Flintec Medical Load Cells 2Health News:Pro-active Manufacturers Save Millions with Advanced Flintec Medical Load Cells 3Health News:Pro-active Manufacturers Save Millions with Advanced Flintec Medical Load Cells 4Health News:Research sheds light on workings of anti-cancer drug 2Health News:Research sheds light on workings of anti-cancer drug 3Health News:Dr. Douglas Macmillan Now Providing LUMINEERS at Research Triangle Dental 2Health News:Onyx Pharmaceuticals Announces December 2009 Investor Events 2
...ry Projects, REDWOOD CITY, Calif., Sept. 26 Gene... today that it has obtained,commitments from sever...ly,12.9 million shares of its common stock and war... purchase the,shares and warrants for $1.84 per un...
... and Interdisciplinary Communication With...la., Sept. 26 Eclipsys,Corporation(R) (Nasdaq: E...at Health First, an integrated healthcare delivery...ults include,reduced duplicate documentation, impr...
...s must be very high , , WEDNESDAY, Sept. 2...and acetaminophen (such as Tylenol), taken togethe... This combo produces a byproduct enzyme that,s tox...minophen, the experts added, but also from large d...
...er Breast Cancer Advocates from ...Sept. 26 "Ignite the Promise: Global,Advocate Sum...er activists,from around the world. The Summit wil...ly detection and treatment,options in their countr...
...,President of Ronco Inventions, Inc., has signed a... implement a new international direct sales and,ma...ulletin Board: NNTN).,During his tenure as Preside... remarked, "Tim Dupler has a,proven track record o...
...akes to Take Place at This Year,s Annual C...NAPOLIS, Md., Sept. 26 CBaySystems, a leading,pro..., today announced that,it will be giving away a ne...s to thank the entire HIM community for,helping to...
Other Medicine News:Health News:Genelabs Technologies Announces Commitments to Raise $23.7 Million in a Registered Direct Financing 2Health News:Eclipsys Knowledge-Based Charting Helps Health First Improve Patient-Care Outcomes 2Health News:Eclipsys Knowledge-Based Charting Helps Health First Improve Patient-Care Outcomes 3Health News:Eclipsys Knowledge-Based Charting Helps Health First Improve Patient-Care Outcomes 4Health News:Caffeine Plus Acetaminophen Toxic for Some 2Health News:Historic Breast Cancer Global Advocate Summit Convenes in Budapest, Hungary on September 29-30 2Health News:Former Ronco President Tim Dupler Signs International Direct Sales and Marketing Contract with Natural Nutrition 2Health News:CBaySystems to Give Away a 2008 Honda Civic at AHIMA 2007 2
(Date:11/27/2009)...LTLAKECITY,Nov.27/PRNewswire-FirstCall/--Booth-364...,apremiersupplierofX-raytubesandflatpaneldigitalim...heRSNAAnnualMeetinginChicago,Ill.fromNovember29-De...chnologyformultiplemodalitiesaswellasspecializedca...llshowcasethelatestX-raytechnologyincluding: ,,...
(Date:11/25/2009)...NOGAPARK,Calif.,Nov.25/PRNewswire/--PraxisElectron...ricanAcademyofFamilyPhysicians,(AAFP)FamilyPractic...provingmedicalquality,healthmaintenance,anddisease...n.Praxisalsoranked#1amongdoctorsindicatingtheirEMR...,Praxisalsorankednumberoneinthecountryinprovidinge...
(Date:11/25/2009)...INCETON,N.J.,Nov.25/PRNewswire-FirstCall/--Pharmas...alcompanycommittedtodiscovering,developingandcomme...dfinancialresultsforthefiscalyearendedSeptember30,...ncash,cashequivalentsandshortterminvestments. ,... ,, Phase2bTrial ,, InlateNovember2009,a...
Breaking Medicine Technology:Varian Medical Systems to Highlight the Latest Digital Detectors, X-ray Tubes and Cancer Treatment Technology at the Radiological Society of North America (RSNA) Annual Meeting in Chicago 2Praxis EMR Wins Top Rankings in 2009 AAFP EHR User Satisfaction Survey 2Pharmasset Reports Fiscal Year End 2009 Financial Results 2Pharmasset Reports Fiscal Year End 2009 Financial Results 3Pharmasset Reports Fiscal Year End 2009 Financial Results 4Pharmasset Reports Fiscal Year End 2009 Financial Results 5Pharmasset Reports Fiscal Year End 2009 Financial Results 6Pharmasset Reports Fiscal Year End 2009 Financial Results 7Pharmasset Reports Fiscal Year End 2009 Financial Results 8Scientists Spot Clue to Cancers Aggressiveness 56441 1Lapatinib shows minimal effect against liver cancer 56439 1Lapatinib shows minimal effect against liver cancer 56439 2Lapatinib shows minimal effect against liver cancer 56439 3Team reveals molecular mechanism underlying a form of diabetes 56437 1Team reveals molecular mechanism underlying a form of diabetes 56437 2
...armaceuticals, a privately-held biopharmaceutical ...ollment in the Company,s second pivotal Phase 3 cl... Together with the previously completed first pivo... fully enrolled its planned pivotal Phase 3 studie...e oral therapy currently in development for the tr...
...ut tumor growth and reduced the risk of disease pr... , - Only once-daily oral cancer treatment to dire...ontrols tumor cell division and blood vessel growt...ntial of Afinitor in multiple additional cancers ,...ed today that Afinitor(R) (everolimus) tablets has...
Other Medicine Technology:QuatRx Completes Enrollment of Ophena(TM)(Ospemifene Tablets) Final Pivotal Phase 3 Study in Women with Postmenopausal Vaginal Atrophy 2QuatRx Completes Enrollment of Ophena(TM)(Ospemifene Tablets) Final Pivotal Phase 3 Study in Women with Postmenopausal Vaginal Atrophy 3Video: Afinitor(R) Approved in US as First Treatment for Patients With Advanced Kidney Cancer After Failure of Either Sunitinib or Sorafenib 2Video: Afinitor(R) Approved in US as First Treatment for Patients With Advanced Kidney Cancer After Failure of Either Sunitinib or Sorafenib 3Video: Afinitor(R) Approved in US as First Treatment for Patients With Advanced Kidney Cancer After Failure of Either Sunitinib or Sorafenib 4Video: Afinitor(R) Approved in US as First Treatment for Patients With Advanced Kidney Cancer After Failure of Either Sunitinib or Sorafenib 5Video: Afinitor(R) Approved in US as First Treatment for Patients With Advanced Kidney Cancer After Failure of Either Sunitinib or Sorafenib 6Video: Afinitor(R) Approved in US as First Treatment for Patients With Advanced Kidney Cancer After Failure of Either Sunitinib or Sorafenib 7Video: Afinitor(R) Approved in US as First Treatment for Patients With Advanced Kidney Cancer After Failure of Either Sunitinib or Sorafenib 8
PelviSoft® Acellular Collagen BioMesh
High Pure Viral RNA Kit
...s a simple, fast and cost-effective method to puri...s system utilizes guanidine thiocyanate and 2-merc...Nase and denature proteins. Purified viral RNA is ... and RNase protection assays. This system is ideal...
MicroReader 4 Plus
Medicine Products: